| Issue |
BIO Web Conf.
Volume 233, 2026
9th International Conference on Advances in Biosciences and Biotechnology: Emerging Innovations in Biomedical and Bioengineering Sciences (ICABB 2026)
|
|
|---|---|---|
| Article Number | 01022 | |
| Number of page(s) | 14 | |
| Section | Biomedical and Health Innovations | |
| DOI | https://doi.org/10.1051/bioconf/202623301022 | |
| Published online | 23 April 2026 | |
Advancing Diagnosis and Therapy of Rare Monogenic Disorders through AI: Insights from Adrenoleukodystrophy
Department of Biotechnology, Jaypee Institute of Information Technology, A-10, Sector 62 Noida, Uttar Pradesh, India- 201309
* Corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Background: Adrenoleukodystrophy (ALD) is a rare X-linked monogenic disorder caused by mutations in the ABCD1 gene, resulting in severe neurologica and adrenal dysfunction. Its phenotypic variability and diagnostic complexity hinder timely intervention.
Objective: This review examines the role of artificial intelligence (AI) in improving the diagnosis, patient stratification, and therapeutic management of ALD, highlighting recent advances and challenges.
Methods: We discuss AI models such as Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), and Random Forest classifiers, focusing on their application to biomarker discovery, multi-omics integration, pathogenic variant identification, and disease modeling. The utility of AI in accelerating drug repurposing and enhancing CRISPRbased gene-editing strategies is also considered.
Results: AI-driven approaches have enabled earlier and more accurate diagnosis of ALD, improved patient stratification, identified potential therapeutic targets, and optimized gene-editing techniques. Integration of clinical and high-throughput multi-omics data enhances predictive modeling and personalized intervention strategies.
Challenges: Despite these advancements, limitations include small datasets, phenotypic heterogeneity, algorithmic opacity, and ethical concerns regarding AI deployment in rare disease management.
Conclusion: AI has transformative potential for ALD and other rare monogenic disorders, providing tools for early diagnosis, precision therapy, and drug development. Future work should focus on expanding datasets, improving interpretability, and addressing ethical considerations to maximize clinical impact.
Key words: Adrenoleukodystrophy / Monogenic disorders / Artificial intelligence / Deep learning / CRISPR
© The Authors, published by EDP Sciences, 2026
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.

